People | February 11, 2025
Peter Bains to replace Jonathan Hunt as CEO of Syngene
Peter Bains has over three decades of experience in the biotech and pharmaceutical industry
Peter Bains has over three decades of experience in the biotech and pharmaceutical industry
CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases
DurA Cycle is designed for large-scale commercial manufacturing of monoclonal antibodies,
NRT offers 50% higher success rate in quitting smoking compared to unassisted attempts
Through the use of robotic assisted orthopaedic surgeries, the success rate is close to 98%
Connectivity and harmonisation were both key driving factors behind our decision to choose the CARA Life Sciences Platform to consolidate our processes
The MOU will involve product collaboration from both companies with a goal of propelling PFAS destruction in groundwater globally
The teams will assist the state health authorities in instituting public health measures and facilitate operationalization of requisite control and containment measures
The team will assist the State Health Authorities in instituting public health measures and facilitate operationalization of requisite control and containment measures
The team will also assist the state health departments in terms of public health measures, management guidelines and protocols to manage the increasing cases of Avian Influenza
Subscribe To Our Newsletter & Stay Updated
